Trial Profile
A trial to estimate inflammatory microscopic tissue injury after cessation of fingolimod or natalizumab in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 26 Feb 2016 New trial record